Description
Key facts
Cell type:HEK-293,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp insertion
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-DDX17, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DDX17 also known as RNA helicase p72 is an enzyme that unwinds RNA molecules. It belongs to the DEAD-box protein family. Its mechanical action involves utilizing ATP to unwind RNA facilitating various RNA processing events. DDX17 weighs approximately 73 kDa making it a relatively large protein. The enzyme expresses in multiple tissues but shows substantial activity in HEK 293 cells a human embryonic kidney cell line.
Biological function summary
This enzyme plays a significant role in RNA metabolism. DDX17 is part of the spliceosome complex which is essential for splicing pre-mRNA into mature mRNA. Through its helicase activity DDX17 ensures the proper remodeling of RNA structures which is necessary for accurate splicing. The protein also contributes to the regulation of gene expression and has been observed to influence transcription factors.
Pathways
RNA processing and maturation are key biological functions of DDX17. The protein integrates into the mRNA splicing pathway where it orchestrates proper RNA folding and splice site selection. Furthermore DDX17 interacts with other DEAD-box proteins such as DDX5 to assist in chromatin remodeling and transcription regulation facilitating efficient gene expression.
Abnormal DDX17 expression or mutation links to certain cancers including breast cancer and leukemia. The protein along with DDX5 affects tumor progression by regulating pathways involved in cell proliferation. These pathways and protein interactions highlight the importance of DDX17 in maintaining normal cell function and its potential as a therapeutic target in cancer treatment.
